Showing results (11-20 of 49) with videos related to

Sort By:
Pageof 5
Rheumatology (Oxford, England)|January 27, 2010
Validity, reliability and responsiveness of the Work Productivity and Activity Impairment Questionnaire in ankylosing spondylitisMargaret C Reilly, Katherine L Gooch, Robert L Wong, et al.
The Journal of Rheumatology|December 4, 2009
Impact of age, sex, physical function, health-related quality of life, and treatment with adalimumab on work status and work productivity of patients with ankylosing spondylitisWalter P Maksymowych, Katherine L Gooch, Robert L Wong, et al.
The Journal of Rheumatology|October 9, 2007
Improvement and longterm maintenance of quality of life during treatment with adalimumab in severe rheumatoid arthritisThomas Mittendorf, Birgitta Dietz, Raimund Sterz, et al.
British Journal of Clinical Pharmacology|August 18, 2023
A first-in-human study of the novel immunology antibody-drug conjugate, ABBV-3373, in healthy participantsRonilda D'Cunha, Hartmut Kupper, Dilek Arikan, et al.
The Journal of Rheumatology|July 3, 2013
Clinical, functional, and radiographic benefits of longterm adalimumab plus methotrexate: final 10-year data in longstanding rheumatoid arthritisEdward C Keystone, Désirée van der Heijde, Arthur Kavanaugh, et al.
Arthritis Research & Therapy|January 28, 2014
Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational studyGerd R Burmester, Marco Matucci-Cerinic, Xavier Mariette, et al.
Rheumatology (Oxford, England)|April 27, 2016
Effect of adalimumab on the work-related outcomes scores in patients with early rheumatoid arthritis receiving methotrexatePaul Emery, Josef S Smolen, Arijit Ganguli, et al.
Arthritis and Rheumatism|June 26, 2008
Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-twoHildrun Haibel, Martin Rudwaleit, Joachim Listing, et al.
Arthritis and Rheumatism|January 1, 2008
Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week studyGerd R Burmester, Gianfranco Ferraccioli, René-Marc Flipo, et al.
Arthritis Care & Research|June 11, 2010
Thresholds of patient-reported outcomes that define the patient acceptable symptom state in ankylosing spondylitis vary over time and by treatment and patient characteristicsWalter P Maksymowych, Katherine Gooch, Maxime Dougados, et al.
Pageof 5